Sox...thanks for the B-UP info. I am very interested in your thoughts on B-OM and the interim results we are supposed to get on the 8th of July. I read that OM occurs in roughly 400,000 patients annually and Leo has indicated that it increases the cost of treatment by about $16K per patient. Assume CTIX could charge $5K per year for B-OM rinse and that only patients who develop OM would use it (the 400K patients). If my math is correct that is about $2B in sales if it becomes the SOC. However, could it be possible that many more patients would use it as a standard preventative when receiving chemo or radiation anywhere on the body? I know typically sales are multiplied many times over to get the value of the indication, so this could be an enormous win for CTIX if the results continue in the right direction, agreed?